- Home
- STTK vs FENC Comparison
STTK vs FENC Comparison
Compare STTK & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STTK | FENC |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.9M | 263.3M |
| IPO Year | 2020 | 2010 |
Fundamental Metrics
Financial Performance| Metric | STTK | FENC |
|---|---|---|
| Price | $5.99 | $7.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $7.00 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 574.2K | 115.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 53.02 | ★ 96.67 |
| EPS | N/A | ★ N/A |
| Revenue | $1,000,000.00 | ★ $47,538,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 123.69 |
| 52 Week Low | $0.69 | $4.68 |
| 52 Week High | $6.13 | $9.92 |
Technical Indicators
Market Signals| Indicator | STTK | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 72.78 | 39.52 |
| Support Level | $1.85 | $7.45 |
| Resistance Level | N/A | $8.27 |
| Average True Range (ATR) | 0.40 | 0.45 |
| MACD | 0.17 | -0.12 |
| Stochastic Oscillator | 89.34 | 10.51 |
Price Performance
Historical ComparisonAbout STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.